Your browser doesn't support javascript.
loading
Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer.
de Boer, Anna Z; Bastiaannet, Esther; de Glas, Nienke A; Marang-van de Mheen, Perla J; Dekkers, Olaf M; Siesling, Sabine; de Munck, Linda; de Ligt, Kelly M; Portielje, Johanneke E A; Liefers, Gerrit Jan.
Afiliación
  • de Boer AZ; Department of Surgery, Leiden University Medical Center, Location J10-71, Postzone K6-R, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. a.z.de_boer@lumc.nl.
  • Bastiaannet E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. a.z.de_boer@lumc.nl.
  • de Glas NA; Department of Surgery, Leiden University Medical Center, Location J10-71, Postzone K6-R, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
  • Marang-van de Mheen PJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Dekkers OM; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Siesling S; Department of Medical Decision-Making, Leiden University Medical Center, Leiden, The Netherlands.
  • de Munck L; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Ligt KM; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
  • Portielje JEA; Department of Health Technology and Services Research, Technical Medical Center, University of Twente, Enschede, The Netherlands.
  • Liefers GJ; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Breast Cancer Res Treat ; 178(3): 637-645, 2019 Dec.
Article en En | MEDLINE | ID: mdl-31451977
PURPOSE: In the Netherlands, radiotherapy after breast-conserving surgery (BCS) is omitted in up to 30% of patients aged ≥ 75 years. Although omission of radiotherapy is considered an option for older women treated with endocrine treatment, the majority of these patients do not receive systemic treatment following Dutch treatment guidelines. Therefore, the aim of this study was to evaluate the effect of omission of radiotherapy on locoregional recurrence risk in this patient population. METHODS: Patients aged ≥ 75 years undergone BCS for T1-2N0 breast cancer diagnosed between 2003 and 2009 were selected from the Netherlands Cancer Registry. To minimize confounding by indication, hospital variation was used to assess the impact of radiotherapy-use on locoregional recurrence risk using cox proportional hazards regression. Hazards ratios with 95% confidence interval (CI) were estimated. RESULTS: Overall, 2390 patients were included. Of the patients with hormone receptor-positive breast cancer, 39.3% received endocrine treatment. Five-year incidences of locoregional recurrence were 1.9%, 2.8%, and 3.0% in patients treated at hospitals with higher (average radiotherapy-use 96.0%), moderate (88.0%), and lower radiotherapy-use (72.2%) respectively, and nine-year incidences were 2.2%, 3.1%, and 3.2% respectively. Adjusted hazard ratios were 1.46 (95% CI 0.77-2.78) and 1.50 (95% CI 0.79-2.85) for patients treated at hospitals with moderate and lower radiotherapy-use, compared to patient treated at hospitals with higher radiotherapy-use. CONCLUSIONS: Despite endocrine treatment in only 39.3%, locoregional recurrence risk was low, even in patients treated at hospitals with lower radiotherapy-use. This provides reasonable grounds to consider omission of radiotherapy in patients aged ≥ 75 years with T1-2N0 breast cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Guideline / Incidence_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Guideline / Incidence_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos